240 related articles for article (PubMed ID: 36553012)
1. MRI-Based Radiomics Nomogram for Predicting Prostate Cancer with Gray-Zone Prostate-Specific Antigen Levels to Reduce Unnecessary Biopsies.
Zhang L; Zhang J; Tang M; Lei XY; Li LC
Diagnostics (Basel); 2022 Dec; 12(12):. PubMed ID: 36553012
[TBL] [Abstract][Full Text] [Related]
2. Predicting prostate cancer in men with PSA levels of 4-10 ng/mL: MRI-based radiomics can help junior radiologists improve the diagnostic performance.
Zhong JG; Shi L; Liu J; Cao F; Ma YQ; Zhang Y
Sci Rep; 2023 Mar; 13(1):4846. PubMed ID: 36964192
[TBL] [Abstract][Full Text] [Related]
3. The potential of a nomogram combined PI-RADS v2.1 and contrast-enhanced ultrasound (CEUS) to reduce unnecessary biopsies in prostate cancer diagnostics.
Liu Y; Wang S; Xiang LH; Xu G; Dong L; Sun Y; Ye B; Zhang Y; Xu H
Br J Radiol; 2022 Sep; 95(1138):20220209. PubMed ID: 35877385
[TBL] [Abstract][Full Text] [Related]
4. Development and Validation of a Radiomics Nomogram for Predicting Clinically Significant Prostate Cancer in PI-RADS 3 Lesions.
Li T; Sun L; Li Q; Luo X; Luo M; Xie H; Wang P
Front Oncol; 2021; 11():825429. PubMed ID: 35155214
[TBL] [Abstract][Full Text] [Related]
5. Biparametric MRI-based radiomics classifiers for the detection of prostate cancer in patients with PSA serum levels of 4∼10 ng/mL.
Lu Y; Li B; Huang H; Leng Q; Wang Q; Zhong R; Huang Y; Li C; Yuan R; Zhang Y
Front Oncol; 2022; 12():1020317. PubMed ID: 36582803
[TBL] [Abstract][Full Text] [Related]
6. Multiparametric MRI-Based Radiomics for Prostate Cancer Screening With PSA in 4-10 ng/mL to Reduce Unnecessary Biopsies.
Qi Y; Zhang S; Wei J; Zhang G; Lei J; Yan W; Xiao Y; Yan S; Xue H; Feng F; Sun H; Tian J; Jin Z
J Magn Reson Imaging; 2020 Jun; 51(6):1890-1899. PubMed ID: 31808980
[TBL] [Abstract][Full Text] [Related]
7. Developing a nomogram based on multiparametric magnetic resonance imaging for forecasting high-grade prostate cancer to reduce unnecessary biopsies within the prostate-specific antigen gray zone.
Niu XK; Li J; Das SK; Xiong Y; Yang CB; Peng T
BMC Med Imaging; 2017 Feb; 17(1):11. PubMed ID: 28143433
[TBL] [Abstract][Full Text] [Related]
8. A nomogram based on PI-RADS v2.1 and clinical indicators for predicting clinically significant prostate cancer in the transition zone.
Wei C; Pan P; Chen T; Zhang Y; Dai G; Tu J; Jiang Z; Zhao W; Shen J
Transl Androl Urol; 2021 Jun; 10(6):2435-2446. PubMed ID: 34295730
[TBL] [Abstract][Full Text] [Related]
9. Use of Radiomics to Improve Diagnostic Performance of PI-RADS v2.1 in Prostate Cancer.
Li M; Yang L; Yue Y; Xu J; Huang C; Song B
Front Oncol; 2020; 10():631831. PubMed ID: 33680954
[TBL] [Abstract][Full Text] [Related]
10. Prostate Cancer Differentiation and Aggressiveness: Assessment With a Radiomic-Based Model vs. PI-RADS v2.
Chen T; Li M; Gu Y; Zhang Y; Yang S; Wei C; Wu J; Li X; Zhao W; Shen J
J Magn Reson Imaging; 2019 Mar; 49(3):875-884. PubMed ID: 30230108
[TBL] [Abstract][Full Text] [Related]
11. Prediction of pelvic lymph node metastasis in prostate cancer using radiomics based on T
Liu X; Zhang Y; Sun Z; Wang X; Zhang X; Wang X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 47(8):1025-1036. PubMed ID: 36097770
[TBL] [Abstract][Full Text] [Related]
12. Biparametric prostate MRI and clinical indicators predict clinically significant prostate cancer in men with "gray zone" PSA levels.
Wei CG; Chen T; Zhang YY; Pan P; Dai GC; Yu HC; Yang S; Jiang Z; Tu J; Lu ZH; Shen JK; Zhao WL
Eur J Radiol; 2020 Jun; 127():108977. PubMed ID: 32330776
[TBL] [Abstract][Full Text] [Related]
13. Development and external validation of a novel nomogram to predict prostate cancer in biopsy-naïve patients with PSA <10 ng/ml and PI-RADS v2.1 = 3 lesions.
Hu C; Sun J; Xu Z; Zhang Z; Zhou Q; Xu J; Chen H; Wang C; Ouyang J
Cancer Med; 2023 Feb; 12(3):2560-2571. PubMed ID: 35920264
[TBL] [Abstract][Full Text] [Related]
14. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
[No Abstract] [Full Text] [Related]
15. Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region.
Zhou Z; Liang Z; Zuo Y; Zhou Y; Yan W; Wu X; Ji Z; Li H; Hu M; Ma L
Prostate; 2022 Apr; 82(5):556-565. PubMed ID: 35098557
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a nomogram for predicting prostate cancer in men with prostate-specific antigen grey zone based on retrospective analysis of clinical and multi-parameter magnetic resonance imaging/transrectal ultrasound fusion-derived data.
Ding Z; Wu H; Song D; Tian H; Ye X; Liang W; Jiao Y; Hu J; Xu J; Dong F
Transl Androl Urol; 2020 Oct; 9(5):2179-2191. PubMed ID: 33209682
[TBL] [Abstract][Full Text] [Related]
17. Predicting the Grade of Prostate Cancer Based on a Biparametric MRI Radiomics Signature.
Zhang L; Zhe X; Tang M; Zhang J; Ren J; Zhang X; Li L
Contrast Media Mol Imaging; 2021; 2021():7830909. PubMed ID: 35024015
[TBL] [Abstract][Full Text] [Related]
18. Using the prostate imaging reporting and data system version 2 (PI-RIDS v2) to detect prostate cancer can prevent unnecessary biopsies and invasive treatment.
Liu C; Liu SL; Wang ZX; Yu K; Feng CX; Ke Z; Wang L; Zeng XY
Asian J Androl; 2018; 20(5):459-464. PubMed ID: 29667616
[TBL] [Abstract][Full Text] [Related]
19. Modified Predictive Model and Nomogram by Incorporating Prebiopsy Biparametric Magnetic Resonance Imaging With Clinical Indicators for Prostate Biopsy Decision Making.
Pan JF; Su R; Cao JZ; Zhao ZY; Ren DW; Ye SZ; Huang RD; Tao ZL; Yu CL; Jiang JH; Ma Q
Front Oncol; 2021; 11():740868. PubMed ID: 34589437
[TBL] [Abstract][Full Text] [Related]
20. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]